Trial · NCT02500043
Results by group64
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 64
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Overall Survival (OS) | TAS-102+BSC | 5.7 | 95% Confidence Interval 4.8 to 6.2 | months | |
| Overall Survival (OS) | Placebo+BSC | 3.6 | 95% Confidence Interval 3.1 to 4.1 | months | |
| Progression-Free Survival (PFS) | TAS-102+BSC | 2.0 | 95% Confidence Interval 1.9 to 2.3 | months | |
| Progression-Free Survival (PFS) | Placebo+BSC | 1.8 | 95% Confidence Interval 1.7 to 1.9 | months | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAE) | TAS-102+BSC | TEAE | 319 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAE) | Placebo+BSC | TEAE | 151 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAE) | TAS-102+BSC | TESAE | 143 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAE) | Placebo+BSC | TESAE | 70 | Participants | |
| Overall Response Rate (ORR) | TAS-102+BSC | 4.5 | 95% Confidence Interval 2.4 to 7.5 | percentage of participants | |
| Overall Response Rate (ORR) | Placebo+BSC | 2.1 | 95% Confidence Interval 0.4 to 5.9 | percentage of participants | |
| Disease Control Rate (DCR) | TAS-102+BSC | 44.1 | 95% Confidence Interval 38.3 to 50.1 | percentage of participants | |
| Disease Control Rate (DCR) | Placebo+BSC | 14.5 | 95% Confidence Interval 9.2 to 21.3 | percentage of participants | |
| Time to Deterioration of European Cooperative Oncology Group (ECOG) Performance Status Score From Baseline | TAS-102+BSC | 4.3 | 95% Confidence Interval 3.7 to 4.7 | months | |
| Time to Deterioration of European Cooperative Oncology Group (ECOG) Performance Status Score From Baseline | Placebo+BSC | 2.3 | 95% Confidence Interval 2.0 to 2.8 | months | |
| Change From Baseline in Quality of Life European Organization for Research and Treatment for Cancer (EORTC) QoL Questionnaire Core 30 (QLQ-C30 Score): Global Health Status | TAS-102+BSC | Cycle 1 | -2.7 | Standard Deviation 17.56 | units on a scale |
| Change From Baseline in Quality of Life European Organization for Research and Treatment for Cancer (EORTC) QoL Questionnaire Core 30 (QLQ-C30 Score): Global Health Status | Placebo+BSC | Cycle 1 | -5.9 | Standard Deviation 22.20 | units on a scale |
| Change From Baseline in Quality of Life European Organization for Research and Treatment for Cancer (EORTC) QoL Questionnaire Core 30 (QLQ-C30 Score): Global Health Status | TAS-102+BSC | Cycle 2 | -5.9 | Standard Deviation 20.51 | units on a scale |
| Change From Baseline in Quality of Life European Organization for Research and Treatment for Cancer (EORTC) QoL Questionnaire Core 30 (QLQ-C30 Score): Global Health Status | Placebo+BSC | Cycle 2 | -7.3 | Standard Deviation 25.80 | units on a scale |
| Change From Baseline in Quality of Life European Organization for Research and Treatment for Cancer (EORTC) QoL Questionnaire Core 30 (QLQ-C30 Score): Global Health Status | TAS-102+BSC | Cycle 3 | -4.1 | Standard Deviation 18.26 | units on a scale |
| Change From Baseline in Quality of Life European Organization for Research and Treatment for Cancer (EORTC) QoL Questionnaire Core 30 (QLQ-C30 Score): Global Health Status | Placebo+BSC | Cycle 3 | -1.4 | Standard Deviation 22.00 | units on a scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02500043/results